Join the Emtricitabine / Tenofovir group to help and get support from people like you.
Emtricitabine / Tenofovir News
2014 to 2021 Saw Increase in HIV Testing, PrEP in Transgender Persons
MONDAY, Dec. 18, 2023 – From 2014 to 2021, there was an increase in the number of transgender persons with an HIV test and who received preexposure prophylaxis (PrEP), according to a study published...
2018 to 2021 Saw Increase in HIV PrEP Provision for Adolescents
MONDAY, Oct. 30, 2023 – From 2018 to 2021, there was an increase in HIV preexposure prophylaxis (PrEP) provision among adolescents, especially among male and older adolescents, according to a study...
Despite New Long-Term Options, People Still Prefer Daily PrEP Pill to Prevent HIV
TUESDAY, Oct. 3, 2023 – New ways to deliver drugs that prevent infection with HIV are out there, but many people still prefer the standard daily PrEP pill, a new study shows. “The oral pill is very e...
Beauty Salon-Based Intervention Builds Knowledge of PrEP in Black Women
THURSDAY, Sept. 14, 2023 – A beauty salon-based intervention improves awareness of and trust in preexposure prophylaxis (PrEP) against HIV among Black cisgender women, according to a study published...
Hypertension, Statin Use Increased for Individuals Using TAF for PrEP
THURSDAY, Sept. 14, 2023 – For individuals taking preexposure prophylaxis (PrEP) for preventing HIV infection, tenofovir alafenamide fumarate (TAF) use is associated with higher incident...
Long-Acting ART Achieves Virologic Suppression for People With HIV
WEDNESDAY, July 5, 2023 – Long-acting antiretroviral therapy (LA-ART) can achieve virologic suppression among people with HIV (PWH), including those with viremia, according to a study published...
Africa's Contribution to HIV Research Low Relative to Its Burden
MONDAY, June 26, 2023 – Africa's contribution to global HIV research is relatively low compared to its burden of infection, according to a study published online June 22 in PLOS Global Public...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada...
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy
FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...
FDA Approves New Combination Pill Stribild for HIV Treatment
August 27, 2012 – The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat...
FDA Approves Truvada for Reducing the Risk of Sexually Acquired HIV Infection
July 16, 2012 – Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Pre-Exposure Prophylaxis, HIV Infection